Processa Pharmaceuticals Stock Today
| PCSA Stock | USD 3.23 0.30 10.24% |
PerformanceWeakest
| Odds Of DistressSmall
|
Processa Pharmaceuticals is trading at 3.23 as of the 6th of January 2026, a 10.24 percent increase since the beginning of the trading day. The stock's open price was 2.93. Processa Pharmaceuticals has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 7th of December 2025 and ending today, the 6th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2017 | Category Healthcare | Classification Health Care |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. The company has 2.27 M outstanding shares of which 3.45 M shares are at this time shorted by private and institutional investors with about 2.06 trading days to cover. More on Processa Pharmaceuticals
Moving against Processa Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Processa Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProcessa Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Processa Pharmaceuticals' financial leverage. It provides some insight into what part of Processa Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Processa Pharmaceuticals (PCSA) is traded on NASDAQ Exchange in USA and employs 10 people. Processa Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.32 M. Processa Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.27 M outstanding shares of which 3.45 M shares are at this time shorted by private and institutional investors with about 2.06 trading days to cover.
Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check Processa Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationProcessa Pharmaceuticals holds 10.73 pct. of its outstanding shares held by insiders and 7.81 pct. owned by third-party entities.
Check Processa Ownership Details
Processa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sbi Securities Co Ltd | 2025-06-30 | 12.0 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 2.0 | |
| Miracle Mile Advisors, Inc. | 2025-06-30 | 0.0 | |
| Armistice Capital, Llc | 2025-06-30 | 0.0 | |
| Hrt Financial Llc | 2025-03-31 | 0.0 | |
| Virtu Financial Llc | 2025-06-30 | 104.7 K | |
| Ubs Group Ag | 2025-06-30 | 64.6 K | |
| Alpine Partners Vi, Llc | 2025-06-30 | 53.4 K | |
| Geode Capital Management, Llc | 2025-06-30 | 50.6 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 41.8 K | |
| Vanguard Group Inc | 2025-06-30 | 24.4 K |
Processa Pharmaceuticals Historical Income Statement
Processa Stock Against Markets
Processa Pharmaceuticals Corporate Management
| James Stanker | Chief Officer | Profile | |
| PharmD Bigora | CoFounder Officer | Profile | |
| Russell MBA | Chief Officer | Profile | |
| Steven MD | Senior Research | Profile | |
| Robert Floyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.